ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Novartis Extends TB Drug Alliance

June 30, 2008 | APPEARED IN VOLUME 86, ISSUE 26

The Novartis Institute for Tropical Diseases, in Singapore, will collaborate with the Global Alliance for TB Drug Development for another five years. The partners hope to develop drug regimens that work faster against all forms of tuberculosis, including drug-resistant TB, and are safe to use in HIV-infected patients. NITD's work with the TB Alliance over the past four years has included the development of nitroimidazopyrans. In 2002, the TB Alliance licensed the nitroimidazole PA-824 from the biotech firm Chiron, which was acquired by Novartis in 2006, and has advanced the compound to Phase II clinical trials.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment